First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

Judy Wells traveled to MSK from Mississippi to be treated for late-stage urothelial carcinoma of the kidney, using a new approach that included an antibody-drug conjugate. A few months later, scans ...

The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...

Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study. This ...

In the exploratory subgroup analysis of chRCC by PD-L1 CPS status, there was a trend favoring nivolumab plus ipilimumab for ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...

Dr. Ignacio Duran titled his discussion of abstracts 2595MO, 2600MO, 2610MO: Bringing any clarity into the non-clear or ...

Jelmyto shows long-term effectiveness in treating low-grade, upper tract urothelial carcinoma, with a high complete response rate in the OLYMPUS trial. The median duration of response for patients ...